TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05834582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Paclitaxel
Description: Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Paclitaxel
Description: Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin+Cyclophosphamide
Description: Epirubicin+Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin+Cyclophosphamide
Description: Epirubicin+Cyclophosphamide
Study: NCT05561075

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pterostilbene free form
Description: One capsule with Pterostilbene free form
Study: NCT04670653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNÓLIA NASAL GEL
Description: Magnólia nasal gel spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOMETASONE FUROATE
Description: Mometasone furoate nasal spray
Study: NCT06408194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22CART infusion
Description: CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
Study: NCT06181617

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Quality of life assessment

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Quality of life assessment
Study: NCT06114966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CADCAM
Description: Milling of Final prosthesis over dental implants using CADCAM milling machine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CADCAM
Description: Milling of Final prosthesis over dental implants using CADCAM milling machine
Study: NCT06181617

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Quality of life assessment
Study: NCT04983901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin/Relebactam
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Given IV or PO
Study: NCT06471166

Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve

Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve
Study: NCT05383950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone application
Description: In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
Study: NCT06111547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
Study: NCT05228457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive intermittent theta-burst stimulation (iTBS)
Description: Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intensive intermittent theta-burst stimulation (iTBS)
Description: Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
Study: NCT05817721

Intervention type: DRUG
Intervention: Proton pump inhibitor
Description: Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not

Intervention type: DEVICE
Intervention: LAMS-implantation
Description: Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis

Intervention type: DEVICE
Intervention: LAMS-implantation
Description: Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
Study: NCT06272214

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
Study: NCT05638880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Description: Valsartan is an angiotensin receptor blocker.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Valsartan is an angiotensin receptor blocker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin is an oral hypoglycemic drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin is an oral hypoglycemic drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
Study: NCT06109922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: 40g bio-active whey protein concentrate powder containing phospholipids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Around 40g pea protein powder not containing phospholipids
Study: NCT06301659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation therapy
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation therapy
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified mirror therapy
Description: The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
Study: NCT05124249

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
Description: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
Description: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment

Intervention type: PROCEDURE
Intervention: PCI
Description: Patients who undergoing PCI
Study: NCT06126445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battery operated toothbrush
Description: Device on plaque removal efficacy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: Device on plaque removal efficacy
Study: NCT04855877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tablet
Description: Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of lactose tablet (placebo)
Study: NCT05951127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Esophagectomy for esophageal cancer and regional lymph nodes dissection.
Study: NCT04913805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate
Description: Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
Description: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride
Description: Active control
Study: NCT05508568

Intervention type: DIAGNOSTIC_TEST
Intervention: ADXBLADDER
Description: ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
Study: NCT05372705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
Study: NCT06512428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simmitinib plus irinotecan liposome
Description: simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome
Description: irinotecan liposome 70 mg/m\^2 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan 180mg/m\^2 every 2 weeks
Study: NCT03954327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
Description: Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (RTF) 600 mg two tablets by mouth once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule [CEBOCAP]
Description: Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
Study: NCT05698628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal perfusion catheterization
Description: Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
Study: NCT05436340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Effect Of Heel Protector In Intensive Care Units
Description: In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
Study: NCT06140082

Intervention type: GENETIC
Intervention: GSTP1 A313G （AA）
Description: Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
Study: NCT06452030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific sensorimotor control training
Description: Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aspecific extension training
Description: Participants allocated to the aspecific group will receive spinal extension exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fascia training
Description: Participants allocated to the fascia group will receive general movement exercises.
Study: NCT05436340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Heel pads will not be used in the control group. Routine maintenance will be applied
Study: NCT05818111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroid
Description: triamcinolone 40mg 4cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid
Description: triamcinolone 40mg 4cc
Study: NCT05698628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal perfusion catheterization
Description: Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
Study: NCT06570603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Efficacy
Description: Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Efficacy
Description: Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Willingness
Description: Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Willingness
Description: Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation about the components and functions of emotion.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation about the components and functions of emotion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation about the components and functions of emotion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation about the components and functions of emotion.
Study: NCT05437068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement (ONS)
Description: ONS plus dietary counseling
Study: NCT05815667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualised Active Communication Education (I-ACE)
Description: The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
Study: NCT04895553

Intervention type: OTHER
Intervention: Observation of ICH and VTE
Description: The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
Study: NCT05936554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: to improve muscle power and balance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional strength training
Description: used in treatment of hemiparetic cerebral palsy and provides postural stability while promoting balance independence with confidence and muscle power
Study: NCT05818111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine 2 % Injectable Solution
Description: xylocaine 2% 4cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 2 % Injectable Solution
Description: xylocaine 2% 4cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline 2cc
Description: normal saline 2cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline 12cc
Description: normal saline 12cc
Study: NCT06206070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Hong Kong version of Westmead Feeling Program 2
Description: Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
Study: NCT06309407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Dosimeters
Description: Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Participants only wore standard chest dosimeters
Study: NCT04650854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study: NCT04859114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.